476060 — Onconic Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- KR₩230bn
- KR₩187bn
- KR₩15bn
Annual cashflow statement for Onconic Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -15,149 | -14,432 | 1,682 | -8,093 |
| Depreciation | ||||
| Amortisation | ||||
| Non-Cash Items | 6,976 | 166 | 1,327 | 5,276 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | -869 | -898 | 670 | -5,477 |
| Change in Accounts Receivable | ||||
| Change in Prepaid Expenses | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Taxes Payable | ||||
| Change in Other Liabilities | ||||
| Other Operating Cash Flow | ||||
| Cash from Operating Activities | -8,859 | -14,964 | 4,140 | -7,841 |
| Capital Expenditures | -8.55 | -2,575 | -1,157 | -141 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | — | — | 38 | 70.4 |
| Sale of Fixed Assets | ||||
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | -8.55 | -2,575 | -1,119 | -70.9 |
| Financing Cash Flow Items | — | 138 | 114 | — |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 27,356 | 25,997 | -39.9 | 19,582 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 18,488 | 8,455 | 2,784 | 12,899 |